Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia. more
Time Frame | BGLC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.62% | -2.08% | -0.57% |
1-Month Return | -19.47% | -2.89% | 1.21% |
3-Month Return | -34.98% | -2.9% | 7.57% |
6-Month Return | -45.7% | 0.21% | 11.45% |
1-Year Return | -61.64% | 7.14% | 28.48% |
3-Year Return | -98.86% | 2.54% | 29.52% |
5-Year Return | -94.71% | 48.91% | 90.66% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 126.95K | 11.39M | 13.36M | 10.93M | 9.77M | [{"date":"2019-12-31","value":0.95,"profit":true},{"date":"2020-12-31","value":85.24,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":81.79,"profit":true},{"date":"2023-12-31","value":73.12,"profit":true}] |
Cost of Revenue | 71.07K | 9.67M | 11.17M | 9.67M | 8.44M | [{"date":"2019-12-31","value":0.64,"profit":true},{"date":"2020-12-31","value":86.59,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.58,"profit":true},{"date":"2023-12-31","value":75.58,"profit":true}] |
Gross Profit | 55.89K | 1.72M | 2.19M | 1.26M | 1.33M | [{"date":"2019-12-31","value":2.55,"profit":true},{"date":"2020-12-31","value":78.39,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":57.39,"profit":true},{"date":"2023-12-31","value":60.6,"profit":true}] |
Gross Margin | 44.02% | 15.10% | 16.42% | 11.52% | 13.61% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":34.3,"profit":true},{"date":"2021-12-31","value":37.29,"profit":true},{"date":"2022-12-31","value":26.17,"profit":true},{"date":"2023-12-31","value":30.91,"profit":true}] |
Operating Expenses | 331.59K | 446.00K | 1.14M | 1.55M | 3.92M | [{"date":"2019-12-31","value":8.45,"profit":true},{"date":"2020-12-31","value":11.37,"profit":true},{"date":"2021-12-31","value":29.01,"profit":true},{"date":"2022-12-31","value":39.51,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (275.70K) | 1.27M | 1.06M | (291.18K) | (2.59M) | [{"date":"2019-12-31","value":-21.64,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":82.89,"profit":true},{"date":"2022-12-31","value":-22.86,"profit":false},{"date":"2023-12-31","value":-203.61,"profit":false}] |
Total Non-Operating Income/Expense | - | (22.63K) | (25.95K) | (24.96K) | (28.44K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2262600,"profit":false},{"date":"2021-12-31","value":-2594600,"profit":false},{"date":"2022-12-31","value":-2495800,"profit":false},{"date":"2023-12-31","value":-2843700,"profit":false}] |
Pre-Tax Income | (275.70K) | 1.26M | 1.04M | (303.66K) | (2.61M) | [{"date":"2019-12-31","value":-21.84,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":82.6,"profit":true},{"date":"2022-12-31","value":-24.05,"profit":false},{"date":"2023-12-31","value":-206.53,"profit":false}] |
Income Taxes | (29.24K) | 168.41K | 291.28K | 52.31K | 21.53K | [{"date":"2019-12-31","value":-10.04,"profit":false},{"date":"2020-12-31","value":57.82,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":17.96,"profit":true},{"date":"2023-12-31","value":7.39,"profit":true}] |
Income After Taxes | - | 1.09M | 751.57K | (355.97K) | (2.63M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":68.69,"profit":true},{"date":"2022-12-31","value":-32.54,"profit":false},{"date":"2023-12-31","value":-240.29,"profit":false}] |
Income From Continuous Operations | (246.47K) | 1.42M | 795.14K | (355.97K) | (3.09M) | [{"date":"2019-12-31","value":-17.32,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":55.86,"profit":true},{"date":"2022-12-31","value":-25.01,"profit":false},{"date":"2023-12-31","value":-217.33,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (246.47K) | 1.09M | 751.57K | (355.97K) | (2.63M) | [{"date":"2019-12-31","value":-22.53,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":68.69,"profit":true},{"date":"2022-12-31","value":-32.54,"profit":false},{"date":"2023-12-31","value":-240.29,"profit":false}] |
EPS (Diluted) | 0.01 | 0.02 | 0.03 | (0.02) | (0.16) | [{"date":"2019-12-31","value":28.72,"profit":true},{"date":"2020-12-31","value":56.4,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-85.12,"profit":false},{"date":"2023-12-31","value":-556.06,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BGLC | |
---|---|
Cash Ratio | 2.92 |
Current Ratio | 4.98 |
Quick Ratio | 3.99 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BGLC | |
---|---|
ROA (LTM) | -10.11% |
ROE (LTM) | -28.44% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BGLC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.15 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.85 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BGLC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.51 |
P/B | 0.50 |
Price/FCF | NM |
EV/R | 0.08 |
EV/Ebitda | 629.53 |
BioNexus Gene Lab Corp Common stock (BGLC) share price today is $0.2601
Yes, Indians can buy shares of BioNexus Gene Lab Corp Common stock (BGLC) on Vested. To buy BioNexus Gene Lab Corp Common stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BGLC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of BioNexus Gene Lab Corp Common stock (BGLC) via the Vested app. You can start investing in BioNexus Gene Lab Corp Common stock (BGLC) with a minimum investment of $1.
You can invest in shares of BioNexus Gene Lab Corp Common stock (BGLC) via Vested in three simple steps:
The 52-week high price of BioNexus Gene Lab Corp Common stock (BGLC) is $1.57. The 52-week low price of BioNexus Gene Lab Corp Common stock (BGLC) is $0.23.
The price-to-earnings (P/E) ratio of BioNexus Gene Lab Corp Common stock (BGLC) is
The price-to-book (P/B) ratio of BioNexus Gene Lab Corp Common stock (BGLC) is 0.50
The dividend yield of BioNexus Gene Lab Corp Common stock (BGLC) is 0.00%
The market capitalization of BioNexus Gene Lab Corp Common stock (BGLC) is $5.21M
The stock symbol (or ticker) of BioNexus Gene Lab Corp Common stock is BGLC